Publications by authors named "Sona Vekaria"
Article Synopsis
- Malignant pleural effusion (MPE) leads to serious issues like breathlessness and reduced quality of life, and the Australasian Malignant PLeural Effusion (AMPLE)-4 trial is investigating whether topical mupirocin can help prevent infections related to the use of indwelling pleural catheters (IPC) in MPE patients.
- The trial is an open-label, randomized study where participants will apply mupirocin or receive standard care, with follow-ups for infection rates and other health impacts over a 6-month period.
- Results from this study aim to clarify the effectiveness of mupirocin for preventing IPC-related infections, potentially shaping future treatment protocols and understanding of infection pathways.
Background And Objective: Indwelling pleural catheter (IPC) and indwelling peritoneal catheter (IPeC) have established roles in the management of malignant pleural and peritoneal effusions but catheter-related infections remain a major concern. Topical mupirocin prophylaxis has been shown to reduce peritoneal dialysis catheter infections. This study aimed to assess the (i) compatibility of IPC with mupirocin and (ii) feasibility, tolerability and compliance of topical mupirocin prophylaxis in patients with an IPC or IPeC.
View Article and Find Full Text PDFIndwelling pleural catheter is an established management for malignant pleural effusions. Extending its use to patients with malignant ascites by insertion of a catheter intraperitoneally enables regular outpatient drainage and improves quality-of-life. However, indwelling pleural/peritoneal catheter (IPC/IPeC) is associated with catheter-related infections, traditionally managed with systemic antibiotics and occasionally requires catheter removal.
View Article and Find Full Text PDFAllergic bronchopulmonary aspergillosis (ABPA) is common in cystic fibrosis (CF). Treatment is challenging and the relapse rate is high. Standard therapy is oral steroids and antifungals.
View Article and Find Full Text PDFIndwelling pleural catheters (IPCs) are effective management options for malignant pleural effusion. Symptomatic fluid loculation is a recognized complication of IPC use and is usually managed with intrapleural instillation of fibrinolytic drugs, such as tissue plasminogen activator (tPA). A previous multicentre observational study showed significant heterogeneity among centres in their dosing regimen for tPA (from 2 to 20 mg) in treating symptomatic loculations.
View Article and Find Full Text PDF